Normally nonmetastatic murine sis-transformed BALB͞c 3T3 cells, transfected with human CD44s gene (hCD44s), acquire spontaneous metastatic capacity to the lung. The mechanism(s) of this facilitated micrometastasis was analyzed in an experimental metastasis model. Human CD44s overexpression promoted the earliest stages severalfold (initial implantation and subsequent stabilization of tumor cells) but was irrelevant for later stages (subsequent outgrowth) of lung experimental micrometastasis. By injecting mixed populations of parental (nonmetastatic) and CD44s-transfected cells, it was shown that cell-cell adhesion between tumor and parental cells was not promoted by hCD44s but that promotion of cell-cell adhesion to lung endothelium or specifically between transfected cells (via hyaluronan) are likely mechanisms. Results obtained with hCD44s-negative primary tumor cells and hCD44s-positive or -negative variants of lung micrometastatic cells (after s.c. injection of transfectants) confirmed the importance of CD44s overexpression for early but not late stages of experimental lung metastasis. Therefore, CD44s represents a metastasis-facilitating molecule that is irrelevant for primary tumor outgrowth but that promotes micrometastasis to the lungs at the very earliest stages.
Metastasis is a complex cascade of interrelated events (1) , successful completion of which depends on the intrinsic variability of tumor cells (2) and host microenvironments (3, 4) . This complexity has made the molecular mechanisms of metastasis difficult to analyze. A number of important molecules have been suggested, including CD44, a cell surface receptor for the high molecular weight glycosaminoglycan hyaluronan (HA) (5) .
CD44 is a heterogeneous family of type I transmembrane glycoproteins with complex alternative-splicing and glycosylation patterns (6) . Interest in CD44 was generated by reports implicating CD44 variant and standard (CD44s) isoforms in tumor metastasis in animal models (5, 7) . Numerous studies of CD44 isoforms as metastasis markers in human cancers, such as colorectal carcinoma (8) (9) (10) and breast cancer (11) (12) (13) (14) , produced variable results.
Studies from our laboratory correlated serum-independent CD44s expression with tumor metastasis in a murine fibrosarcoma͞metastasis model system [i.e., BALB͞c 3T3 cells transformed with sis or ras oncogenes (15) (16) (17) ]. The involvement of CD44s in metastasis was tested more directly by transfecting the human CD44s gene (hCD44s) into two different nonmetastatic fibrosarcoma cell types. They demonstrated induction of spontaneous metastasis by overexpression of hCD44s (18) . In contrast, hCD44s overexpression was selected against during primary tumor outgrowth; this expression was down-regulated in primary tumors by an epigenetic mechanism involving methylation of the human CD44s gene.
In this study, the mechanism(s) of induction of metastatic capacity by hCD44s expression was analyzed using tail vein injections into nude mice and quantitation of pulmonary micrometastases by virtue of the drug resistance markers of the tumor cells. By analyzing both early and late stages of lung colonization, our results show that hCD44s overexpression strongly facilitates the retention of tumor cells in the pulmonary vasculature and their subsequent colonization of the lung.
MATERIALS AND METHODS
Cell Lines for This Study. Cell lines have been described (15) (16) (17) (18) . In brief, c-sis-transformed BALB͞c 3T3 cells (HUSI, the parental cells) were transfected with an expression plasmid containing the hCD44s cDNA. Two stable transfectants (clones 5 and 6) from independent transfections expressing hCD44s on the cell surface were chosen. After s.c. injection of transfectants into nude mice, several primary and lung metastatic tumor cell lines were isolated and are used herein: 5.2, primary tumor cells from transfectant 5, negative for hCD44s expression; 6.5.1, lung metastatic cells from transfectant 6, hCD44s-positive; and 6.5.2, a variant of 6.5.1 that has lost hCD44s expression. Cells were grown in DMEM plus 10% newborn calf serum (GIBCO͞BRL).
Experimental Metastasis and Colony Growth Assays. Transfected͞transformed or tumor cells were detached from tissue culture plates by brief trypsinization, and complete medium was added to inhibit trypsin. Cells were rinsed with PBS and resuspended in PBS at 10 6 cells͞ml. Cell suspensions (10 5 cells in 100 l) were injected into tail veins of female athymic nude mice (6-8 weeks old with three mice per datum point unless specified otherwise). Mice were killed postinjection (1 h, 24 h, or 4 weeks). Lungs were dispersed into culture with 0.25% (wt͞vol) trypsin͞50 mM EDTA͞PBS for 45 min at 37°C with shaking. Cells from each lung were plated in complete medium onto four tissue culture plates; 48 h later, drug selection (either 200 g͞ml hygromycin B or 3 g͞ml puromycin) was initiated. When drug-resistant colonies grew out (Ϸ2 weeks after the initiation of selection), two plates per lung were stained with Coomassie blue, and colonies were Abbreviation: HA, hyaluronan; CD44s, CD44 standard isoform; hCD44s, human CD44s; SWM, stain-wash medium; FITC-HA, FITCconjugated high molecular weight HA; HUSI, parental sistransformed 3T3 cells ‡ To whom reprint requests should be addressed. e-mail: lac7@po. cwru.edu. enumerated; the rest of the cells was used for fluorescenceactivated cell sorter (FACS) analyses (see below). The number of tumor cells in lung was determined by multiplying the number of colonies on a plate after selection by the number of plates. For mixed-population experiments, the number of hCD44s transfectant cells was determined as n 1 ϭ n of puromycin-resistant colonies. The number of parental HUSI cells was established using the following formula: n 2 ϭ n of hygromycin-resistant colonies Ϫ n 1 (19, 20) ] was added to 50 l of cell suspension. After a 1-h incubation on ice, cells were rinsed with cold SWM, and 50 l of fluorescein isothiocyanate conjugate of a secondary antibody (1:40 diluted in SWM) was added to the cells for 1 h. Cells were then washed four times in SWM and analyzed on a FACScan flow cytometer (Becton Dickinson). Negative controls included using normal mouse immunoglobulin G instead of primary antibody and staining parental HUSI cells with A.3 or 7.10 antibody.
FITC-conjugated high molecular weight HA (FITC-HA) has been described (19) . It was dissolved in SWM and added to cells for 1 h. After four washes in SWM, cells were analyzed on FACScan. Controls included preincubation of cells with unconjugated HA or with antibodies specific for human CD44 (7.10).
RESULTS hCD44s Overexpression Facilitates Lung Colonization of
Tumor Cells After i.v. Injection. hCD44s overexpression induces lung micrometastasis formation in normally nonmetastatic c-sis-transformed 3T3 cells (HUSI; ref. 18) in two independent isolates (transfectants 5 and 6). Analysis suggested that hCD44s overexpression was important after the tumor cells had entered the bloodstream (data not shown). To test this possibility directly, experimental metastasis assays were performed comparing parental HUSI cells and hCD44s transfectant 5. Cells were injected into the tail veins of athymic nude mice; at different times postinjection (1 h, 24 h, or 4 weeks), mice were killed, their lungs were dispersed, and cells were plated onto 100-mm tissue culture plates. Tumor cells were quantitated using a colony growth assay based on the drug resistance phenotype of tumor cells. After hygromycin B selection, plates were stained with Coomassie blue, and colonies were counted. Lung-Colonizing Cells Have Elevated Cell Surface hCD44s and HA Binding. Selective pressures for hCD44s overexpression during lung colonization were analyzed next by comparing CD44 levels in cells recovered from the lungs vs. cells maintained in continuous culture for the same time period. hCD44s transfectant cells tended to lose their hCD44s expression when maintained in tissue culture ( Fig. 2A) . In Fig. 2B , enrichment for hCD44s-expressing cells as a selected subpopulation is evident from lungs 1 h postinjection. This enrichment is greater at the 24-h time point (Fig. 2C ). Although cells from lungs 4 weeks postinjection contained more hCD44s protein than cells in culture for the same length of time (Fig. 2D) , this difference was less pronounced than that from cells at earlier time points. ''Recovered'' cells eventually lost their hCD44s expression upon longer term culturing, suggesting that selection for hCD44s overexpression in micrometastatic selectants was extremely strong, enabling us to detect it even after culture outgrowth and drug selection over a 2-week period. Therefore, hCD44s expression is most beneficial for the earliest stages of microvessel establishment͞extravasation but may not be beneficial for later metastasis outgrowth.
The binding of HA was evaluated for transfectant cells maintained in culture or recovered from the lungs at different time points. Parental HUSI cells do not bind HA (Fig. 3A) . In contrast, transfectant cells recovered from lungs at 24 h (Fig.  3B) bind significantly more HA than cells maintained in culture (Fig. 3C) or recovered after 4 weeks of lung growth (data not shown). Furthermore, this binding can be inhibited Proc. Natl. Acad. Sci. USA 94 (1997) partially with 7.10 antibody specific for human CD44 (Fig. 3B) . These results offer a basis for selection of hCD44s variants during early stages of lung colonization. hCD44s-Mediated Cell-Cell Adhesion Specific for Transfected Cells and͞or with the Lung Endothelium as Likely Mechanisms of Action. Two mechanisms for hCD44s may be envisioned: (i) hCD44s could facilitate cell-cell adhesion with increased retention of cell aggregates in lung vasculature and͞or (ii) it promotes adhesion of cells to endothelial cells and͞or basement membrane. If heterotypic cell-cell interaction was critical, two predictions can be made: (i) metastasis of transfectants would be decreased when coinjected with parental cells and (ii) selection for hCD44s overexpressors would be stronger in the resulting lung metastatic populations. The exception would be if transfected cells adhere to each other specifically via the overexpressed form of hCD44s, perhaps via HA. Parental HUSI and transfectant 5 cells were mixed at different ratios (80%:20%, 50%:50%, and 20%:80%) and mixtures were injected (10 5 cells) into tail veins. At 24 h, lungs were dispersed into culture for analysis. Two different selectable markers were used: hygromycin to recover all tumor cells and puromycin to recover hCD44s transfectants only. Table 1 shows no reduction in the efficiency of lung colonization by hCD44s-expressing cells when coinjected with increasing numbers of parental HUSI cells. These data also show that parental cells formed 40 Ϯ 29 colonies per 10 5 injected cells at the 24-h time point whereas transfectants formed 764 Ϯ 131. This difference is highly significant when analyzed statistically by a two-tailed heteroscedastic t test (P ϭ 6.4 ϫ 10
Ϫ10
). Therefore, hCD44s may not function by inducing cell-cell adhesion between tumor cells and parental cells but may do so specifically between transfected cells (cell-cell adhesion mediated by HA, perhaps) or via interactions with the lung microvasculature.
Cell surface hCD44s protein levels were analyzed next in populations of tumor cells recovered from lungs of animals injected with different ratios of parental cells and hCD44s transfectants. Fig. 4 shows very similar levels of hCD44s in transfectant cell populations from animals receiving mixtures of parental and transfectant cells relative to populations from injection of pure transfectant cells (Fig. 2C) . These findings support the conclusions above.
Experimental Metastasis of Primary Tumor and Lung Micrometastatic Cells Derived from hCD44s Transfectants. hCD44s-negative primary tumor and hCD44s-positive lung micrometastatic cell lines were isolated after s.c. injection of hCD44s transfectants (18) . These cells were used to test whether hCD44s expression was required for experimental metastasis of these in vivo-selected tumorigenic variants.
Primary tumor cells (5.2 cells) that had lost hCD44s protein by an epigenetic mechanism were injected i.v. into nude mice. A slight increase was seen in colonization number relative to untransfected cells at 1-and 24-h time points; this increase was not statistically significant (compare 5.2 cells in Fig. 5 with HUSI cells in Fig. 1 ). The number of colonies was much smaller, however, than the number of colonizers with transfectant cells (compare 5.2 cells with transfectant 5 cells in Fig. 1 ). Of interest, the tumor cells recovered from the lungs showed some staining for hCD44s protein, suggesting again selection for hCD44s (data not shown). The animals killed at 4 weeks displayed extensive lung metastasis (Fig.  5C ). Tumor cells were recovered from the lungs of both animals and were negative for hCD44s protein (data not shown), indicating that this expression was not required for tumor outgrowth.
FIG. 2. hCD44s overexpression is selected for during early stages of micrometastasis. FACS was performed as described in Materials and
Methods. In brief, nonpermeablized cells were incubated with control (mouse immunoglobulin G, negative control) or anti-human CD44 (A. Finally, micrometastasis of hCD44s-positive lung micrometastatic cells [after s.c. injection of transfectant 6 (6.5.1 cells)] was tested. These tumor cells express sizable amounts of hCD44s. As shown in Fig. 5 , lung colonization efficiency of these cells was similar to that of hCD44s transfectants at 1 h and 24 h; these second-round tumor cells recovered from lungs contained very high levels of hCD44s (data not shown). At 4 weeks, large metastases also were detected (Fig. 5C ). Cells from these lungs with late-stage disease contained much lower levels of hCD44s protein (data not shown).
From 6.5.1 cells, a spontaneously arising variant was isolated (6.5.2 cells) that had lost hCD44s expression. When these cells were i.v.-injected (Fig. 5) , they formed significantly fewer colonies than 6.5.1 cells at 24 h, further demonstrating the importance for hCD44s in lung colonization. However, these cells were significantly more metastatic than Experimental metastasis assays were performed as described in Materials and Methods and in the legend to Fig. 1 . Number of transfectant-derived colonies was determined by puromycin selection; number of HUSI-derived colonies was determined by subtracting the number of puromycinresistant colonies from the number of hygromycin-resistant colonies. In light of our findings, it recently was shown that CD44 and its binding to HA mediate adhesion of lymphocytes to a model endothelium under physiological flow conditions (22) . Overexpression of hCD44s in our tumor model also elevated hyaluronan binding; whether this property is also critical for promotion of experimental micrometastasis remains to be tested more directly.
Whereas hCD44s overexpression was selected for during early stages of experimental metastasis, it was irrelevant (or even counterproductive) during the outgrowth of overt metastases. Cells from large lung metastases had very low levels of FACS-detectable cell surface hCD44s. The metastatic phenotype is expressed by a minor subpopulation of cells in primary tumors (23) ; these same properties may be irrelevant or disadvantageous for tumor outgrowth at a given site and, therefore, be only transiently expressed in these subpopulations (3). Our results suggest that CD44s may be a critical part of such a transient metastatic phenotype.
Studies on the expression of CD44 in human clinical cancer specimens have produced variable results, suggesting that CD44 may not be required for metastasis of some human cancers (24) . Our results offer potential explanation for these disparate results, contrasting with the promising studies with animal models (5, 7, 18) . If CD44 is important for micrometastasis but irrelevant or disadvantageous for tumor outgrowth as suggested by our results, the variable expression of CD44 would be expected in human clinical tumor specimens that are principally derived from large clinically detectable tumors. Clearly, much more study of gene regulation is required at the earliest stages of malignant progression in human cancer, particularly those that are transient.
